For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...
HealthDay on MSN10h
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & DiabetesPopular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have other untapped potentials to reduce health risks.
A study by Washington University School of Medicine and the VA St. Louis Health Care System has found that GLP-1 drugs can have both health benefits and risks, including reduced risks of ...
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback